Seroprevalence of SARS-CoV-2 in a Cohort of Patients with Multiple Sclerosis under Disease-Modifying Therapies
Sancho-Saldaña, Agustín (Hospital Arnau de Vilanova (Lleida, Catalunya))
Gil Sánchez, Anna (Universitat de Lleida)
Quirant, Bibiana (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia)
Nogueras, Lara (Universitat de Lleida)
Peralta, Silvia (Fundació Esclerosi Múltiple (Lleida, Catalunya))
Solana, Maria José (Hospital Arnau de Vilanova (Lleida, Catalunya))
González-Mingot, Cristina (Hospital Arnau de Vilanova (Lleida, Catalunya))
Gallego, Yhovanni (Hospital Arnau de Vilanova (Lleida, Catalunya))
Quibus, Laura (Hospital Arnau de Vilanova (Lleida, Catalunya))
Ramo-Tello, Cristina (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Presas Rodríguez, Sílvia (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Martínez Cáceres, Eva María (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia)
Torres, Pascual (Universitat de Lleida)
Hervás, José Vicente (Hospital de Sant Joan Despí Moisès Broggi (Sant Joan Despí, Barcelona))
Valls, Joan (Institut de Recerca Biomèdica de Lleida)
Brieva Ruiz, Luis (Hospital Arnau de Vilanova (Lleida, Catalunya))

Data:	2022
Resum:	Background: Disease-modifying therapies (DMTs) used to treat multiple sclerosis (MS) alter the immune system and therefore increase the risk of infection. There is growing concern about the impact of COVID-19 on patients with MS (pwMS), especially those treated with DMTs. Methods: This is a single-center prospective observational study based on data from the Esclerosis Múltiple y COVID-19 (EMCOVID-19) study. Demographic characteristics, MS history, laboratory data and SARS-CoV-2 serology, and symptoms of COVID-19 in pwMS treated with any DTM were extracted. The relationship among demographics, MS status, DMT, and COVID-19 was evaluated. Results: A total of 259 pwMS were included. The administration of interferon was significantly associated with the presence of SARS-CoV-2 antibodies (26. 4% vs. 10. 7%, p = 0. 006). Although patients taking interferon were significantly older (49. 1 vs. 43. 5, p = 0. 003), the association of interferon with the presence of SARS-CoV-2 antibodies was still significant in the multivariate analysis (OR 2. 99 (1. 38; 6. 36), p = 0. 006). Conclusions: According to our data, pwMS present a higher risk of COVID-19 infection compared with results obtained from the general population. There is no evidence of a worse COVID-19 outcome in pwMS. DMTs did not significantly change the frequency of COVID-19, except for interferon; however, these findings must be interpreted with caution given the small sample of pwMS taking each DMT.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Multiple sclerosis ; COVID-19 ; SARS-CoV-2 ; DMT ; Seroprevalence
Publicat a:	Journal of clinical medicine, Vol. 11 (april 2022) , ISSN 2077-0383

DOI: 10.3390/jcm11092509
PMID: 35566632

10 p, 273.4 KB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats